INCY – Incyte Corporation

Incyte Corporation

INCY

$72.11

Name : Incyte Corporation

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $13,955,015,680.00

EPSttm : 0.15

Incyte Corporation

$72.11

1.02%

$0.73

Float Short %

3.04

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.03

EPS Last/This Y

EPS This/Next Y

0.97

Price

72.12

Target Price

77.42

Analyst Recom

2.35

Performance Q

-6.31

Relative Volume

0.77

Beta

0.76

Ticker: INCY

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	INCY	72.54	0.49	0.18	25353
2025-01-24	INCY	72.54	0.47	3.03	26549
2025-01-27	INCY	72.64	0.48	0.14	26917
2025-01-28	INCY	73.13	0.48	1.15	27023
2025-01-29	INCY	73.73	0.50	0.10	27541
2025-01-30	INCY	73.75	0.47	0.07	30039
2025-01-31	INCY	74.14	0.47	0.45	30205
2025-02-03	INCY	73.72	0.47	0.64	33287
2025-02-04	INCY	74.12	0.47	0.26	33841
2025-02-05	INCY	75.29	0.49	0.08	33335
2025-02-06	INCY	74.95	0.48	0.22	34212
2025-02-07	INCY	74.17	0.48	0.47	34404
2025-02-10	INCY	68.3	0.47	0.40	37657
2025-02-11	INCY	66.34	0.41	0.66	41264
2025-02-12	INCY	69.08	0.42	0.65	42695
2025-02-13	INCY	70	0.42	0.19	43038
2025-02-14	INCY	70.42	0.42	0.15	43860
2025-02-18	INCY	71.29	0.41	0.32	44311
2025-02-19	INCY	70.19	0.41	1.71	44443
2025-02-20	INCY	71.36	0.42	0.18	44573
2025-02-21	INCY	72.15	0.41	0.14	45048
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	INCY	72.53	47.3	1149.3	1.30
2025-01-24	INCY	72.54	47.3	1146.8	1.30
2025-01-27	INCY	72.64	47.3	1147.6	1.30
2025-01-28	INCY	73.13	47.3	1157.6	1.30
2025-01-29	INCY	73.72	47.3	1159.3	1.30
2025-01-30	INCY	73.77	47.3	1147.8	1.30
2025-01-31	INCY	74.14	49.6	1154.7	1.30
2025-02-03	INCY	73.74	49.6	1137.4	1.30
2025-02-04	INCY	74.12	49.6	1153.9	1.30
2025-02-05	INCY	75.29	49.6	1172.5	1.30
2025-02-06	INCY	74.98	49.6	1140.6	1.30
2025-02-07	INCY	74.16	49.6	1129.6	1.30
2025-02-10	INCY	68.30	49.6	1019.2	1.30
2025-02-11	INCY	66.31	49.6	1145.8	5.16
2025-02-12	INCY	69.07	49.6	1174.7	5.16
2025-02-13	INCY	70.01	49.6	1044.9	5.83
2025-02-14	INCY	70.42	49.6	921.3	5.80
2025-02-18	INCY	71.30	64.5	930.9	5.80
2025-02-19	INCY	70.16	64.5	890.1	5.74
2025-02-20	INCY	71.37	64.5	937.9	5.74
2025-02-21	INCY	72.12	64.5	927.9	5.74
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	INCY	-1.88	-9.05	2.69
2025-01-24	INCY	-1.88	-9.05	2.69
2025-01-27	INCY	-1.88	-9.16	2.69
2025-01-28	INCY	-1.90	-9.16	2.66
2025-01-29	INCY	-1.90	-9.16	2.66
2025-01-30	INCY	-1.41	-9.16	2.66
2025-01-31	INCY	-1.41	-9.16	2.66
2025-02-03	INCY	-1.41	-7.65	2.66
2025-02-04	INCY	-1.41	-7.65	2.66
2025-02-05	INCY	-1.41	-7.65	2.66
2025-02-06	INCY	-1.41	-7.65	2.66
2025-02-07	INCY	-1.41	-7.65	2.66
2025-02-10	INCY	-1.41	-6.76	2.66
2025-02-11	INCY	-1.38	-6.76	2.66
2025-02-12	INCY	-1.38	-6.76	3.05
2025-02-13	INCY	-1.37	-6.76	3.04
2025-02-14	INCY	-1.44	-6.76	3.04
2025-02-18	INCY	-1.07	-3.83	3.04
2025-02-19	INCY	-1.12	-3.83	3.04
2025-02-20	INCY	-1.12	-3.83	3.04
2025-02-21	INCY	-1.14	-3.83	3.04
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

1.43

Avg. EPS Est. Current Quarter

1.05

Avg. EPS Est. Next Quarter

1.46

Insider Transactions

-1.14

Institutional Transactions

-3.83

Beta

0.76

Average Sales Estimate Current Quarter

1004

Average Sales Estimate Next Quarter

1157

Fair Value

102.12

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

34.7

Max Drawdown 5-Year %

-53.3

Target Price

77.42

P/E

265.89

Forward P/E

11.31

PEG

2.76

P/S

3.29

P/B

4.05

P/Free Cash Flow

56.03

EPS

0.27

Average EPS Est. Cur. Y

5.74

EPS Next Y. (Est.)

6.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

0.77

Relative Volume

0.77

Return on Equity vs Sector %

-18.3

Return on Equity vs Industry %

-2.7

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.36

EBIT Estimation

927.9

Incyte Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 2617

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

stock quote shares INCY – Incyte Corporation Stock Price stock today

news today INCY – Incyte Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch INCY – Incyte Corporation yahoo finance google finance

stock history INCY – Incyte Corporation invest stock market

stock prices INCY premarket after hours

ticker INCY fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

INCY – Incyte Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: INCY

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y